Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

News Conference News AHA 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

November 13, 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

News Conference News AHA 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Michael O'Riordan

November 11, 2025

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

News Conference News AHA 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

November 06, 2022

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

News Conference News AHA 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

November 20, 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

News Conference News AHA 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Yael L. Maxwell

November 17, 2019

Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery

News Conference News AHA 2017

Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery

November 14, 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

News Conference News AHA 2014

Registry: Newer P2Y12 Inhibitors Reduce Stent Thrombosis, Mortality Over Clopidogrel

Yael L. Maxwell

November 17, 2014

News Conference News AHA 2014

Vorapaxar Safe in NSTE-ACS But Bleeding Risk Merits 6-Month Delay Before Noncardiac Surgery

Yael L. Maxwell

November 16, 2014

News Conference News AHA 2014

Extending Clopidogrel Past 1 Year Improves Outcomes in DES, But Not BMS Patients

Yael L. Maxwell

November 16, 2014

News Conference News

AIDA STEMI: No Advantage for Intracoronary vs. Intravenous Abciximab

November 13, 2011

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.